The Role of F-18 Florbetapir in the Early Detection of Cardiac Amyloidosis
Sponsor: Avid Radiopharmaceuticals
Terminated
Low enrollment
Other terminated trials from Avid Radiopharmaceuticals
Other Cardiac Amyloidosis trials with similar outcome
Listed as NCT03040427, this PHASE4 trial focuses on Cardiac Amyloidosis and remains terminated or withdrawn. Sponsored by Avid Radiopharmaceuticals, it has been updated 11 times since 2017, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE4
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE4
-
Sep 2021 — Dec 2022 [monthly]
Terminated PHASE4
▶ Show 6 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Terminated PHASE4
-
Feb 2020 — Jan 2021 [monthly]
Terminated PHASE4
Status: Recruiting → Terminated
-
Jan 2019 — Feb 2020 [monthly]
Recruiting PHASE4
-
Jun 2018 — Jan 2019 [monthly]
Recruiting PHASE4
-
Jul 2017 — Jun 2018 [monthly]
Recruiting PHASE4
Phase: NA → PHASE4
-
Feb 2017 — Jul 2017 [monthly]
Recruiting NA
First recorded
Jan 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Avid Radiopharmaceuticals
- The Cleveland Clinic
For direct contact, visit the study record on ClinicalTrials.gov .